Inhibikase Therapeutics, Inc. (IKT) Misses Q1 EPS by 2c
Tweet
Share
E-mailGet Alerts IKT Hot Sheet
Join SI Premium – FREE
Inhibikase Therapeutics, Inc. (NASDAQ: IKT) reported Q1 EPS of ($0.16), $0.02 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $64.52 thousand.
For earnings history and earnings-related data on Inhibikase Therapeutics, Inc. (IKT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- L3Harris CEO steps down amid conduct review, shares drop
- Traws Pharma (TRAW) Tops Q2 EPS by 27c
- InspireMD (NSPR) Tops Q2 EPS by 1c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
